Atebimetinib with gemcitabine and nab-paclitaxel achieved a 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.
Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type or GOF mutations.